Chimeric Therapeutics Limited (ASX: CHM) - Share Price
- Current share price for CHM : $0.074
Chimeric Therapeutics Limited (CHM), an ASX-listed company, operates as a clinical stage cell therapy entity focused on expanding access to cell therapy for patients with cancer. The entity concentrates on the discovery, development, and commercialization of cell therapies through a team experienced in cell therapy research and refinements.
CHM General Information +
| ASX Code | CHM |
| Website | http://www.chimerictherapeutics.com |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 4 |
| CHM Share Price | $0.074 |
| Day High | $0.075 |
| Day Low | $0.071 |
| Last Close | $0.074 |
| CHM Share Price Movement | - ( No change ) |
Prices as at 16:40, 16 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Chimeric Therapeutics Limited (CHM) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Chimeric Therapeutics Limited (CHM) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Chimeric Therapeutics Limited (CHM) price-sensitive announcements
CHM - CHM announces positive Phase 1/2 data at ASCO
Chimeric Therapeutics announced promising results from their Phase 1/2 study of CHM CDH17,
Chimeric Therapeutics Limited (CHM)
1 Jun 2026 | 8:27 AM
1 Jun 2026 | 8:27 AM
CHM - Quarterly Activities/Appendix 4C Cash Flow Report
Chimeric Therapeutics Limited reported significant advancements in its clinical programs a
Chimeric Therapeutics Limited (CHM)
29 Apr 2026 | 3:41 PM
29 Apr 2026 | 3:41 PM
CHM - CHM CORE-NK Phase 1B clinical trial achieves 60% CR/CRi
Chimeric Therapeutics Limited, an Australian leader in cell therapy, announced that their
Chimeric Therapeutics Limited (CHM)
27 Apr 2026 | 9:15 AM
27 Apr 2026 | 9:15 AM
CHM - Consolidation/Split - CHM
Chimeric Therapeutics Limited announced a security consolidation of their ordinary shares
Chimeric Therapeutics Limited (CHM)
19 Mar 2026 | 8:26 AM
19 Mar 2026 | 8:26 AM
Chimeric Therapeutics Limited (CHM) Recent ASX Announcements
CHM Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$6.88 | -$50.90 | -67.90% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$11.57 | -$158.50 | -71.70% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$25.50 | -$560.60 | 44.90% | 0.00 | 0.00 | 0.00% | 0.0% |
CHM Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Chimeric Therapeutics Limited (CHM) | $4M | -0.6790 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| CSL Limited (CSL) | $50,540M | 0.1108 | -0.1347 | 0.0438 | 11.3160 | 13.0770 | 12.5286 | 4.22% | 3.40% | 3.53% |
| Clinuvel Pharmaceuticals Limited (CUV) | $466M | 0.0287 | 0.0233 | 0.0942 | 12.8830 | 12.5902 | 11.5064 | 0.54% | 0.78% | 1.26% |
| Mesoblast Limited (MSB) | $2,531M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $4,680M | -1.3893 | 0.0000 | -0.1295 | 0.0000 | 258.7242 | 297.1983 | 0.00% | 0.00% | 0.00% |
CHM Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 0.76 | 0.00 |
| Market | 0.30 | 13.20 | 1.18 | 0.68 |
| Sector | 0.40 | 27.30 | 2.51 | 2.19 |
CHM Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Bradley Glover | Non-Executive Chairman, Non-Executive Director | 16 Feb 2026 |
| Mr Phillip Hains | Non-Executive Director | 12 Jul 2023 |
| Dr Lesley Russell | Non-Executive Director | 28 Aug 2020 |
| Mr Eric Sullivan | Non-Executive Director | 30 Aug 2023 |
| Professor H. Miles Prince | Non-Executive Director | 1 Jul 2025 |
Chimeric Therapeutics Limited (CHM) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 19 Aug 2025 | PRINCE, H. Miles | Buy | Indirect Shares | 4,273,142 | $0.004 | $14,955.997 |
| 30 Apr 2025 | HOPPER, Paul | Issued | Indirect Shares | 10,000,000 | $0.005 | $50,000.000 |
| 30 Apr 2025 | HAINS, Phillip | Issued | Indirect Shares | 2,608,696 | $0.005 | $13,043.480 |
See all changes in directors' interest & trades for Chimeric Therapeutics Limited (CHM) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
CHM Management
| Name | Position |
|---|---|
| Jason Litten | Chief Medical Officer (CMO) |
| Nathan Kim -liung Jong | Joint Company Secretary |
CHM Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Chimeric Therapeutics Limited (CHM). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 204,994,574 (6.30%) | Paul Hopper |
CHM Calendar of Events
| Date | Event |
|---|---|
| 26 February 2027 | Report (Interim) |
| 28 August 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
